Clinical trials: Glioblastoma
Glioblastoma
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
This is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and stereotactic radiosurgery (SRS) for recurrent Glioblastoma (GBM).
- Trial name
- NCT04225039
- Testing
- INCMGA00012, INCAGN01876, SRS
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Pennsylvania
Adult Glioblastoma, Depression
Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma
This clinical trial is studying magnetic resonance spectroscopy imaging in predicting response in patients to vorinostat and temozolomide in patients with recurrent, progressive, or newly diagnosed glioblastoma.
- Conditions
- Adult Glioblastoma, Depression, Recurrent Adult Brain Tumor
- Trial name
- NCT01342757
- Testing
- vorinostat, temozolomide, magnetic resonance spectroscopic imaging
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00892177
- Testing
- bevacizumab, dasatinib
- Where
- 305 sites in United States
- Volunteers
- 144 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Glioblastoma Multiforme, Anaplastic Astrocytoma
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
This study will offer a safe treatment for patients with relapsing recurring glioblastoma (GBM) or anaplastic astrocytoma (AA). The trial will test the hypothesis that Erlotinib (Tarceva, OSI-774) can be safely used up to a dose…
- Trial name
- NCT00301418
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
Phase I/II trial to study the effectiveness of erlotinib in treating patients who have recurrent malignant glioma or recurrent or progressive meningioma.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT00045110
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis, pharmacological study
- Where
- 7 sites in United States
- Volunteers
- 136 people
- Sponsor
- National Cancer Institute (NCI)
Glioma
Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00795665
- Testing
- bevacizumab, carmustine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, Davis
Glioblastoma Multiforme
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
In this phase I/II study,investigators are evaluating the feasibility and efficacy of the combination of BKM120, an oral inhibitor of PI3 kinase, and bevacizumab in the treatment of patients with relapsed/refractory GBM.
- Trial name
- NCT01349660
- Testing
- Bevacizumab, BKM120
- Where
- 8 sites in United States
- Volunteers
- 88 people
- Sponsor
- SCRI Development Innovations, LLC
Glioblastoma
Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma
This is a pilot study to determine the efficacy and safety of aldoxorubicin in subjects with glioblastoma who have progressed following surgery and prior treatments.
- Trial name
- NCT02014844
- Testing
- 250 mg/m2 aldoxorubicin, 350 mg/m2 aldoxorubicin
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- ImmunityBio, Inc.
Glioblastoma Multiforme of Brain
Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme
This is a safety and tolerability study looking at the addition of avelumab, an immune checkpoint inhibitor, to standard therapy of temozolomide and radiotherapy in patients with newly diagnosed glioblastoma multiforme.
- Trial name
- SEJ (NCT03047473)
- Testing
- avelumab
- Where
- Canada
- Volunteers
- 38 people
- Sponsor
- Clinique Neuro-Outaouais
Malignant Glioma, Glioblastoma
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
This is a Phase 1/2 clinical trial to evaluate a new combination of drugs, marizomib (MRZ) and bevacizumab (BEV; Avastin®), for the treatment of WHO Grade IV malignant glioma.
- Trial name
- NCT02330562
- Testing
- MRZ, BEV
- Where
- 5 sites in United States, Canada
- Volunteers
- 121 people
- Sponsor
- Celgene
Glioblastoma, Gliosarcoma
A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma
This study will determine the efficacy of the small molecule CDK4/6 inhibitor PD 0332991 (as measured by progression free survival at 6 months) in patients with recurrent glioblastoma multiforme or gliosarcoma who are Rb…
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma
- Trial name
- PD0332991 (NCT01227434)
- Testing
- PD 0332991 (pre-surgery), PD 0332991, Resection as clinical care
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of California, San Francisco
Malignant Glioma, Glioblastoma Multiforme
A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)
The primary objective of the study is to use 24 week survival to assess the efficacy of the combination of Gliadel followed by Avastin and irinotecan in the treatment of grade IV malignant glioma patients following surgical…
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Gliosarcoma
- Trial name
- NCT00735436
- Testing
- Gliadel/Avastin/CPT-11
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Duke University
Recurrent Glioblastoma, Recurrent Astrocytoma
PARP Inhibition for Gliomas (PI-4G or π4g)
The purpose of this study is to determine what effects (good and bad) niraparib has on patients with recurrent brain cancer.
- Conditions
- Recurrent Glioblastoma, Recurrent Astrocytoma, Recurrent Oligodendroglioma, Recurrent Glioma
- Trial name
- OU-SCC-PI-4G (NCT05297864)
- Testing
- Niraparib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Oklahoma
Neoplasms
Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma
First in human, open-label, dose escalation (Phase I) and expansion study (Phase 2a) of oral lisavanbulin (BAL101553) in adult patients with advanced solid tumors and adult patients with recurrent or progressive glioblastoma…
- Trial name
- NCT02490800
- Testing
- Lisavanbulin Phase 1 dose escalation portion, Lisavanbulin Phase 2a expansion portion
- Where
- 13 sites in Belgium, Germany and 2 more
- Volunteers
- 72 people
- Sponsor
- Basilea Pharmaceutica
Glioblastoma, Gliosarcoma
Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
Primary objective: To determine the 6-month progression free survival of patients with recurrent glioblastoma multiforme (GBM) treated with Erlotinib plus Sirolimus.
- Trial name
- NCT00672243
- Testing
- Erlotinib + sirolimus
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Duke University
Glioblastoma, Recurrent Glioblastoma
VB-111 in Surgically Accessible Recurrent/Progressive GBM
This research study is studying a new viral cancer therapy, ofranergene obadenovec (VB-111), for recurrent or progressive glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment.
- Trial name
- NCT04406272
- Testing
- VB11, Surgery, Bevacizumab
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Dana-Farber Cancer Institute
Glioblastoma, Glioma
Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas
This is an open-label, multicenter, Phase 2 study to evaluate the efficacy and safety of oral selinexor in participants with recurrent gliomas.
- Trial name
- KING (NCT01986348)
- Testing
- Selinexor
- Where
- 6 sites in United States, Denmark and 1 more
- Volunteers
- 76 people
- Sponsor
- Karyopharm Therapeutics Inc
Glioblastoma
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)
The primary purpose of the study is to evaluate the efficacy and safety of early postsurgery temozolomide chemotherapy followed by the standard temozolomide regimen, compared to the standard regimen alone, for the treatment of…
- Trial name
- NCT00686725
- Testing
- Temozolomide, Radiotherapy
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Glioblastoma Multiforme, Malignant Gliomas
Sunitinib to Treat Recurrent Brain Cancer
Background: One way tumors are able to grow is by forming new blood vessels that supply them with nutrients and oxygen. Sunitinib blocks certain proteins on the surface of tumor and blood vessel cells that are involved with the…
- Conditions
- Glioblastoma Multiforme, Malignant Gliomas, Anaplastic Gliomas
- Trial name
- NCT00923117
- Testing
- Sutent (sunitinib)
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
This is a phase 2, multicenter study to determine the safety and efficacy of ICT-107 in treating a type of brain tumor called Glioblastoma Multiforme (GBM).
- Trial name
- NCT01280552
- Testing
- ICT-107
- Where
- 25 sites in United States
- Volunteers
- 124 people
- Sponsor
- Precision Life Sciences Group